News

As part of the transaction, Actavis will pay Auden £306m in cash and two-year royalty on a percentage of gross profits of one of Auden Mckenzie’s products. Actavis

Around 160 men aged 18 to 64 with sexual dysfunction related to secondary hypogonadism, or low levels of testosterone will be included in the randomized, double-blind, placebo-controlled, parallel

Lenvima is an orally administered molecular targeted agent which inhibits the activities of several different molecules including VEGFR, FGFR, RET, KIT and PDGFR. It particularly inhibits VEGFR, FGFR

This is the first combination of BRAF/MEK inhibitors to demonstrate a statistically significant overall survival benefit for this patient population in two Phase III studies. Results are being

ASP2215 is a receptor tyrosine kinase inhibitor of FLT3 and AXL, which are involved in the growth of cancer cells. ASP2215 demonstrated inhibitory activity against FLT3 internal tandem

Conducted by the ECOG-ACRIN Cancer Research Group as part of Exelixis’ collaboration with the US National Cancer Institute (NCI), the Study E1512 is a randomized phase II trial

In CheckMate -017, at one year, Opdivo showed an overall survival rate of 42% versus 24% for docetaxel, with a median overall survival of 9.2 months versus six

The product will be launched under the name Junel Fe 24 (norethindrone acetate and ethinyl estradiol tablets USP and ferrous fumarate tablets) and is currently available in the

MM-398 is a new, stable nanotherapeutic encapsulation of the marketed chemotherapy drug irinotecan. The filing follows the recent submissions of NDA and marketing authorization application (MAA) by its